Director, Commercial Project Management & Launch Excellence

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

In June 2026, Remix announced an agreement to merge with Passage Bio, with the combined company expected to operate as Remix Therapeutics and trade on Nasdaq. The announced transaction included a concurrent $100 million private placement intended to support continued development of its pipeline. Remix remains focused on translating its RNA-processing science into meaningful treatment options for patients with significant unmet medical needs.

Position Summary:

The Director will translate commercial strategy into an actionable enterprise launch plan, align stakeholders around priorities, and drive accountability for delivery